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Abstract A novel drug named Dasatinib is a highly
potent ATP-competitive orally active dual Src/Abl kinase
inhibitor with anti-proliferative activity against solid
tumors and CML (chronic myeloid leukaemia) cell lines.
Dasatinib has been shown to have preclinical activity
against human prostate, breast, pancreatic, lung, and head
and neck cancer. To determine whether Dasatinib can
inhibit the growth of laryngeal squamous cell carcinoma, in
the present study, we investigated the antitumor effect of
Dasatinib on Hep-2 cells. Hep-2 cells were treated with
different concentrations of Dasatinib for different time.
Cell proliferation, cell cycle distribution, and cell apoptosis
were evaluated using MTT assay, flow cytometry, and
fluorescent microscopy. It was found that Dasatinib
exhibited significant efficacy in growth inhibition, cell
cycle arrest at G0/G1 phase, and apoptosis induction in a
dose- and time-dependent manner. Measuring the modu-
lation of regulators in the cell cycle, apoptosis and signal
transductions by western blot analysis showed that the
effect of Dasatinib was due to suppression of the expres-
sion of Bax, Bcl-2, Caspase-3, and Caspase-8. Moreover,
in vivo studies were performed in a nude mouse xenograft
model, the new prescription (DDP ? Dasatinib) was better
than DDP alone in terms of therapeutic efficacy. In con-
clusion, the antitumor effect of Dasatinib on Hep-2 cells
was due to the induction of cell cycle arrest as well as
apoptosis. The possible mechanisms underlying the action
might be attributed to the suppression of Src phosphory-
lation. This investigation suggests a potential clinical
application of Dasatinib for the treatment of laryngeal
cancer patients
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Introduction
Laryngeal squamous cell carcinoma is one of the most
common squamous cell carcinomas of the head and neck.
Laryngeal carcinoma ranks the 11th common kind of
cancer in men worldwide, with a tendency toward an
increasing occurrence of new cases and deaths annually
[1]. More than 95 % of all laryngeal cancers are squamous
cell carcinomas. The traditional treatment for squamous
cell carcinoma of the larynx was surgery, usually total
laryngectomy in advanced cases, followed by radiotherapy.
During the last decades, combined modality approaches
have been developed, and chemotherapy has been con-
firmed as a major component of these treatment approaches
to enhance loco-regional disease control, reduce distant
metastasis, and improve survival in patients with advanced
laryngeal cancer [2]. Therefore, the therapeutic strategies,
which are able to produce greater efficacy and preserve
larynx as well, are essential to this concept [3]. However,
potential complications and side effects of this drug limit
its application in Laryngeal carcinoma chemotherapy,
which may account for the failure of chemotherapy in
patients with advanced laryngeal carcinoma. In this regard,
novel effective chemotherapeutic agents are desperately
needed in the treatment of laryngeal cancer to improve
survival and to enhance larynx preservation.
Src is the prototypic member of a family of nine non-
receptor tyrosine kinases [SFKs (Src family kinases),
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which include Src, Lyn, Fyn, Lck, Hck, Fgr, Blk, Yrk, and
Yes] that has a key role in many cellular signaling path-
ways [4]. SFKs regulate four main cellular functions that
ultimately control the behavior of transformed cells: cell
proliferation, adhesion, invasion, and motility [5]. Src is
overexpressed in head and neck squamous cell carcinoma
relative to control tissues. Src offers particularly a prom-
ising molecular target for anticancer therapy, so we want to
use Src kinase inhibitor to inhibit the signaling pathways
and to decrease the growth of laryngeal carcinoma.
A novel drug named Dasatinib (BMS-354825, SPRY-
CEL; Bristol-Myers Squibb) is a highly potent ATP-
competitive orally active dual Src/Abl kinase inhibitor with
anti-proliferative activity against solid tumors and CML
(chronic myeloid leukaemia) cell lines. It sensitively
inhibits all members of the Src family, including c-Src,
Lck, Fyn, and Yes. At higher concentrations (3–28 nmol/
L), Dasatinib also inhibits the Src kinases Abl, c-Kit,
PDGFR, and EphA2 [6]. Dasatinib has been shown to have
preclinical activity against human prostate, breast, pan-
creatic, lung, head and neck cancer, mesotheliomas, and
sarcomas dependent on Src kinase [7].
To date, no study has been conducted in the evaluation
of the effect of Dasatinib on human laryngeal cancer cells.
As constitutive activation of P-Src has been determined in
head and neck squamous cell carcinoma, and blockade of
Src signaling has been shown to effectively inhibit cell
growth and induce apoptosis in head and neck squamous
cell carcinoma cells, we hypothesized that Dasatinib would
be useful in treating human laryngeal cancer cells. To test
this hypothesis, we designed the present study to examine
the antitumor effect of Dasatinib in vitro and in vivo on
human laryngeal cancer cells, including the effects on cell
growth, cell cycle distribution, apoptosis, and the expres-




Dasatinib (Mr, 488.0) was obtained from Bristol-Myers
Squibb. For in vitro use, Dasatinib was dissolved in
DMSO at a concentration of 10 mg/mL. The solution was
aliquoted and kept at -20 C until use. Frequent freeze-
thawing was avoided. For in vivo use, Dasatinib was
dissolved in citrate buffer and this solution was kept at
0–4 C for up to 14 days. Cisplatin (EMD Biosciences,
Inc.) was dissolved in 10 mg/ml of DMSO for both
in vitro and in vivo use. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazoliumbromide (MTT) was from Fluka,
USA. Propidium iodide (PI) was from Biosharp, USA.
Annexin V-FITC apoptosis detection kit was from Jingmei
Biotech Co. Ltd., Shenzhen, China. Bcl-2, Bax, caspase-3,
caspase-8, and actin primary antibodies, as well as the
secondary antibody were obtained from Santa Cruz Bio-
technology Inc., CA, USA. Anti-phosphorylated Src anti-
body (p-Src Tyr 416) and total Src antibody were both
obtained from Cell Signaling Technologies. Dulbecco’s
modified Eagle’s medium (DMEM), and fetal calf serum
(FCS) were obtained from Gibco BRL (Grand Island, NY,
USA). Other laboratory reagents were obtained from
Sigma, USA. Fluorescence microscopy (Olympus, Japan)
and flow cytometry (FACScalibur, Becton–Dickinson,
USA) were employed.
Animals
Twenty male nude mice (3 months old, weighing
20 ± 2 g) were obtained from China Medical University
animal facility and fed with purified water and a com-
mercial stock diet in an air-conditioned room at 20–22 C.
All the animals were treated softly and equally. All animals
were killed by cervical dislocation method. All the research
was approved by The Institutional Animal Care and Use
Committee of China Medical University.
Cell culture
Human laryngeal cancer line Hep-2 was bought from Cell
Bank, Shanghai Institutes for Biological Sciences, Chinese
Academy of Sciences, Shanghai and cultured in RPMI
1640 supplemented with 10 % FBS, 100 U/ml penicillin G,
and 100 lg/ml streptomycin. Cultures were maintained in a
5 % CO2 humidified atmosphere a 37 C.
Cell growth inhibition assay
The MTT assay was performed to assess viability of the
human laryngeal cancer line Hep-2 after treatment with
0.1, 1 and 10 mg/ml Dasatinib. 96-well plate cultures, after
exposure to the control or test solutions for a specific time
period (observed at 12, 24, and 36 h), were incubated with
50 mg/ml MTT at a dilution of 1:10 based on the volume
of culture medium for 3 h at 37 C. At the end of the
incubation time, the MTT solution was removed and
150 ml DMSO was added to each well and stirred to dis-
solve the dark-blue formazan crystals which had formed.
The proportion of viable cells was determined by mea-
suring the optical density of each sample at 480 nm with a
spectrophotometer. Three cultures were exposed to each
solution at each time period. The means of each group of
cultures were compared.
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Cell cycle analysis by flow cytometry
Cell cycle analyses were carried out using DNA flow
cytometry. Hep-2 cells (1 9 106/well) were seeded in six-
well plates and allowed to attach overnight. Cells were
treated with 0.1, 1 and 10 mg/ml Dasatinib for 24 h and
harvested by 0.25 % trypsin. The cells were then washed
twice with PBS, centrifuged at 1,000 r/min for 5 min, and
fixed in 70 % ethanol at 4 C. Before DNA analysis, the
cells were washed again with PBS, treated with 50 lg/ml
of RNase, and stained with 100 lg/ml of PI in the dark.
Flow cytometry analyses were carried out on a FAC-
SCalibur instrument using the ModFit program.
Cell apoptosis analysis by annexin V/PI staining
Cell apoptosis was assessed by measuring membrane
redistribution of phosphatidylserine using an Annexin
V-FITC apoptosis detection kit according to the manufac-
turer’s protocol. In brief, cells (1 9 106/well) were plated
in six-well plates and allowed to attach overnight, Cells
were treated with 0.1, 1 and 10 mg/ml Dasatinib for 24 h,
washed twice with chilled PBS, resuspended in 250 ll of
binding buffer, and stained with staining solution con-
taining Annexin V-FITC and PI. After incubation in the
dark for 30 min, cells were analyzed by FACSCalibur
instrument.
Hoechst 33258 staining in situ detection of cell injury
The human laryngeal cancer line Hep-2 was cultured to
subconfluence in a six chamber slide with 10 % FCS
containing DMEM. This was then added to (1) serum-free
DMEM; (2) 0.1 mg/ml Dasatinib; (3) 1 mg/ml Dasatinib;
and (4) 10 mg/ml Dasatinib. After treatment with Dasatinib
or DMEM control, cells were fixed with cold methanol and
acetic acid (3/1, v/v) at 4 C overnight and stained with
Hoechst 33258 for 30 min in the dark, washed again in
PBS, and finally observed with a fluorescence microscope
(Olympus, Japan).
Western blot analysis
The human laryngeal cancer line Hep-2 was cultured to
subconfluence in a 60 mm culture dish with 10 % FCS
containing DMEM. The medium was then changed to
either (1) serum-free DMEM; (2) 0.1 mg/ml Dasatinib; (3)
1 mg/ml Dasatinib; and (4)10 mg/ml Dasatinib. Protein
was extracted in a standard lysis buffer with proteinase
inhibitors (sodium orthovanadate, phenylmethylsulfonyl
fluoride, leupeptin, and aprotinin obtained from BioShop
Burlington, ON, Canada), 20 mg of protein lysate was
electrophoresed with a 12 % SDS-PAGE gel, transferred to
a nylon membrane, and probed with an antibody for total
Src, p-Src, Bcl-2, Bax, caspase-3, and caspase-8. Following
incubation with the secondary antibody, blots were devel-
oped by an ECL western blot substrate kit (Abcam, USA).
Antitumor activity in the nude mouse tumor
xenograft model
All animal studies were carried out in accordance with the
‘‘Guide for the Care and Use of Laboratory Animals.’’
Hep-2 cells, 5 9 106 cells per 0.2 ml in PBS, were injected
subcutaneously into the right armpit. Tumor size was
measured every other day in two dimensions using caliper,
and tumor volume was calculated using the formula, ab2/2,
where b is the smaller dimension. When tumors reached
about 150 mm3, animals were randomized (five animals/
group) into four groups. Rats in the normal saline (NS)
group were injected with NS into the caudal vein for
22 days. Rats in the cisplatin group were treated with
100 mg/m2 of cisplatin injected into the caudal vein on the
first day, followed by 21 days of NS administration. Rats in
the Dasatinib group were injected with 10 mg/m2 of Da-
satinib into the caudal vein for 22 days. Rats in the cis-
platin ? Dasatinib group were treated with 100 mg/m2 of
cisplatin on the first day and 10 mg/m2of Dasatinib for
22 days injected into the caudal vein.
Tumor inhibition rate
The inhibitory effect on tumor growth was evaluated by the
tumor inhibition rate. Twenty-two days after administra-
tion, rats were anesthetized with ethyl ether and killed, and
the whole body and tumor were weighed immediately. The
inhibition rates of FAT solid tumor growth were calculated
according to the formula, inhibition rate (%) = (1-mean
weight of tumor in the drug treated groups/mean weight of
tumor in the NS group) 9 100 %.
Statistical analysis
All values are expressed as mean ± SD. Statistical analysis
was performed using the Student’s t test. A value of
p \ 0.05 was considered significant.
Results
Dasatinib inhibited cellular proliferation
in a dose- and time-dependent manner
Accumulated evidences have shown that Dasatinib inhibits
the growth of numerous human cancer cell lines [8]. To
evaluate the effect of Dasatinib on cell growth of human
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laryngeal cancer cell line Hep-2, we employed MTT assay
to assess cell growth inhibition. Hep-2 cells were grown in
the presence or absence of various concentrations of Da-
satinib for 1–2 days and showed dose -and time-dependent
inhibition of cell proliferation (Fig. 1).
Dasatinib-induced Hep-2 cells G0/G1 arrest
Most anticancer agents exhibit their inhibitory effects on
tumor cell growth by inducing cell cycle arrest and apop-
tosis. A recent report has demonstrated that Dasatinib
induces G0/G1 arrest and apoptosis in human breast cancer
cell lines [9]. To gain insights into the mechanism by
which cell reduction is achieved, we investigated the effect
of Dasatinib on cell cycle distribution by FACS analysis,
and the results were summarized in (Fig. 2). A 24 h
exposure of Hep-2 cells to different concentrations of
Dasatinib caused an enrichment of cells in G0/G1 phase in
a dose-dependent manner (P \ 0.05 vs control), accom-
panied by a reduction in S/G2 M phase cells (P \ 0.05 vs.
control).
Annexin V/PI staining for cell apoptosis
To demonstrate the cell apoptosis induced by Dasatinib, we
employed flow cytometry analysis with Annexin V/PI
staining. Following FACS, Xuorescence of PI was plotted
over Annexin V-FITC Xuorescence (Fig. 3). Healthy cells
have low FITC Xuorescence and low PI Xuorescence (Q3).
Early apoptotic cells have high FITC Xuorescence but low
PI Xuorescence (Q4). Late apoptotic cells have high FITC
Xuorescence and high PI Xuorescence (Q2). Dead cells
have low FITC Xuorescence but high PI Xuorescence
(Q1). As shown in Fig. 3, the percentage of apoptotic cells
(Q2 ? Q4) induced by Dasatinib significantly increased
with the increasing concentration (P \ 0.05, or 0.01 vs.
control).
In situ detection of cell injury
After Hep-2 cells were treated with Dasatinib (0.1, 1,
10 mg/ml) for 24 h, marked morphological changes asso-
ciated with cell injury such as condensation of chromatin,
nuclear fragmentation, and apoptotic bodies were clearly
observed using Hoechst 33258 staining (Fig. 4). Compared
with the control group, a significant increase in the number
of impaired cells was noted following Dasatinib treatment.
Dasatinib reduced the level of Src activation
Given the Hep-2 cell line to concentration of Dasatinib, we
compared the expression of total Src and P-Src level. We
found that the Src activation (i.e., the level of P-Src), but
not total Src expression, was correspondingly inhibited by
Dasatinib in a dose-dependent manner (Fig. 5).
Fig. 1 Viability of Hep-2 cells after treatment with Dasatinib. Hep-2
cells were treated with Dasatinib (0.1, 1.0, 10 mg/mL) for 12, 24 and
36 h. MTT assays were performed in triplicate for each data point
Fig. 2 Effect of dasatinib on the cell cycle progression in Hep-2 cell
line. Cells were blocked at the G1 phase transition by dasatinib. The
cells were incubated for 24 h with dasatinib and, subsequently, the
cell cycle profile was analyzed by flow cytometry. The percentages of
cells in the G0/G1-phase and in the S-, G2- and M-phases are shown.
Dasatinib induced a G1 cell cycle arrest in all of the cells tested
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Dasatinib modulates the expression of apoptosis-related
proteins in Hep-2 cells
The mechanisms that underlie the combined effects of
dasatinib on apoptosis-related proteins (caspase-3, caspase-
8, Bax, bcl-2) were investigated. The levels of these pro-
teins were evaluated using western blot analysis. Figure 6
shows that caspase-3, caspase-8, and Bax protein levels
increased after 48 h of treatment with Dasatinib, while the
level of bcl-2 protein decreased. Beta-actin was used as the
loading control.
Antitumor effect of Dasatinib on Hep-2 xenograft
model
Twenty-two days after administration of Dasatinib, the
mean tumor weights in the treatment groups decreased
significantly compared with those in the control group
(p \ 0.05). In cisplatin group, the Dasatinib group, and the
cisplatin ? Dasatinib group, the tumor inhibition rates were
50, 37.5 and 62.5%, respectively. The difference in tumor
inhibition was significant between the cisplatin group and
the cisplatin ? Dasatinib group (p \ 0.05) (Fig. 7).
Discussion
The non-receptor tyrosine kinase Src is known to promote
cell proliferation, survival, and decreased adhesion, as well
as increased motility, invasiveness, and angiogenesis, all of
which promote the neoplastic phenotype [10]. Kinases are
also excellent targets for anticancer therapy, as they work
as a molecular switch, their regulation is reversible and
rapid, and does not require new protein synthesis. Based on
molecular targeting therapy, improper patient selection by
predictive biomarkers leads to the success [11].
In the present study, we first examined the inhibitory
effect of Dasatinib on cell viability and proliferation of
Hep-2 cells. Using MTT assay, we observed that Dasatinib
inhibited Hep-2 cells proliferation in a dose- and time-
dependent fashion (Fig. 1). To our knowledge, this is the
first study to demonstrate that Dasatinib exhibits antitumor
effect on human laryngeal cancer cell line. A recent report
has demonstrated that Dasatinib induces G0/G1 arrest and
apoptosis in human breast cancer cell lines [12]. To
determine whether Dasatinib induces cell cycle arrest and
apoptosis in Hep-2 cell line, we performed a series of
experiments on cell cycle distribution and apoptosis. Flow
Fig. 3 Induction of apoptosis in
cells after Dasatinib treatment.
Apoptosis of cells was
evaluated by measuring the
exposure of phosphatidylserine
on the cell membranes using an
Apoptosis Detection Kit. The
apoptosis rates of the cell lines
treated with 0.1, 1.0, 10 mg/mL
Dasatinib increased remarkably
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cytometry analysis showed that the administration of Da-
satinib resulted in an accumulation of cells at G0/G1 phase
(Fig. 2). Fluorescent microscopy observation by Hoechst
33258 staining showed that treatment of Hep-2 cells with
Dasatinib led to the occurrence of typical morphological
changes of apoptosis (Fig. 4). Flow cytometry analysis
with Annexin V/PI staining indicated that Dasatinib-
induced Hep-2 cell apoptosis in a dose- and time-
dependent manner (Fig. 3). These data suggested that the
inhibitory of Dasatinib against this cell line was due to the
induction of cell cycle arrest as well as apoptosis.
To better understand the signaling mechanism that
affected Dasatinib, we examined the effects of agent on the
phosphorylation status of Src. As expected, Dasatinib
treatment of Hep-2 cells inhibited serum-induced Src
phosphorylation. We found that the Src activation (i.e., the
level of P-Src), but not total Src expression, was corre-
spondingly inhibited by Dasatinib in a dose-dependent
manner (Fig. 5). These suggested degradation of P-Src
mediated Dasatinib-induced apoptosis in Hep-2 cells. Da-
satinib inhibited Hep-2 cells proliferation, induced G0/G1
arrest, and apoptosis by reducing the level of Src activation.
Dasatinib may induce apoptosis through mitochondria-
dependent and death receptor-dependent apoptotic path-
ways. Dasatinib suppresses cancer cell growth by inhibiting
proliferation through the promotion of caspase-dependent
apoptosis. Caspases are cytoplasmic aspartate-specific
cysteine proteases, and it plays an important role in apop-
tosis [13]. The death receptor-dependent apoptotic pathway
is triggered at the cell surface and requires activation of
Fig. 4 Cell apoptosis observed
by Hoechst 33258 staining.
Hep-2 cells were treated with
solvent control a, 0.1 b, 1 c, and
10 mg/mL d Dasatinib for 24 h.
From 0 to 10 mg/mL, the
number of apoptotic cell
increased gradually, while the
number of total cells decreased
Fig. 5 Effects of Dasatinib on P-Src and Total-Src protein expression
in Hep-2 cells. Hep-2 cells were treated with Dasatinib (0.1, 1.0 and
10 mg/mL) for 24 h. The protein levels were monitored by western
blot analysis
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caspase-8, whereas the mitochondrion-dependent pathway
is initiated by the release of mitochondrial cytochrome c into
the cytoplasm and requires activation of caspase-9. Subse-
quently, caspase-8 or -9 can activate caspase-3, which in
turn targets and degrades specific and vital cellular proteins,
ultimately resulting in nuclear DNA degradation and apop-
totic cell death [14]. It is obvious that activation of caspases
is central to the execution of apoptosis [15]. Bcl-2, an
inhibitor of the mitochondrial apoptosis pathway, exerts its
action by blocking proapoptotic counterparts, which in turn
prevents the release of cytochrome c and the activation of
caspases [16]. Bax is a death promoter, which is neutralized
by heterodimerization with Bcl-2. Bax translocates into the
outer mitochondrial membrane followed by leakage of
cytochrome c from the mitochondria into the cytosol [17].
Caspase-9 and caspase-3 are activated sequentially, and this
event then leads to the breakdown of chromosomal DNA.
There is a significant possibility that Dasatinib-mediated
anti-apoptosis of Hep-2 cells is the result of regulation of
Bcl-2 and Bax. Hence, identification of the target com-
pounds is necessary. We found a negative correlation
between Bcl-2 expression and Dasatinib-induced apoptosis.
In the evaluation of the efficacy of Dasatinib in vivo,
drug treatment in the nude mouse model utilizing Hep-2
cells produced a significant reduction in tumor burden. The
Dasatinib-induced reduction in tumor weight was compa-
rable to that produced by the conventional chemothera-
peutic agent DDP. In this study, DDP and Dasatinib were
combined to enhance antitumor activities. This new pre-
scription (DDP ? Dasatinib) was better than DDP alone in
terms of therapeutic efficacy. Complexities of cell signal-
ing in advanced cancer including recurrent HNSCC may
result in the activation of feedback mechanisms. Therefore,
the combination of molecular targeted therapy is a rational
approach. We found that Dasatinib can enhance the effect
of Cisplatin providing the basis for combination of Da-
satinib with Cisplatin to treat HNSCC. A pharmacody-
namic study shows that Src activity is inhibited by
Dasatinib (at a dosage of 100 mg/day) rapidly, but recov-
ered within 6–12 h [18]. Because Dasatinib 100 mg/day is
well-tolerated, dose escalation is a possible strategy to
overcome the recovery of Src activity.
The antitumor activity against Hep-2 cells mediated via
Dasatinib was due to the induction of cell cycle arrest as
well as apoptosis. The possible mechanisms underlying the
action might be attributed to the suppression of Src phos-
phorylation relevant to the regulation of cell cycle and
apoptosis. Dasatinib ? DDP are more effective in inhibit-
ing the growth of Hep-2 cells than either agent alone.
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